Compare SABS & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | SPCE |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 250.2M |
| IPO Year | N/A | 2017 |
| Metric | SABS | SPCE |
|---|---|---|
| Price | $3.92 | $2.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $10.75 | $3.06 |
| AVG Volume (30 Days) | 924.9K | ★ 7.9M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,544,000.00 |
| Revenue This Year | N/A | $2,270.73 |
| Revenue Next Year | N/A | $880.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $2.13 |
| 52 Week High | $6.60 | $5.59 |
| Indicator | SABS | SPCE |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 57.53 |
| Support Level | $3.54 | $2.91 |
| Resistance Level | $4.11 | $3.39 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 42.71 | 88.82 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.